Boston Scientific: Latest Medinol Allegations Without Merit

Apr 26, 2001, 01:00 ET from Boston Scientific Corporation

    NATICK, Mass., April 26 /PRNewswire/ -- Boston Scientific Corporation
 (NYSE:   BSX) announced today that Medinol Ltd. has added a claim to its lawsuit
 against the Company alleging that Boston Scientific misappropriated Medinol's
 NIRFlex(TM) stent technology and incorporated it into Boston Scientific's
 internally developed Express(TM) stent.  Medinol is the supplier of the NIR(R)
 stent sold exclusively by Boston Scientific.
     "Apparently, Medinol's game plan is 'the best defense is a good offense',"
 said Boston Scientific spokesman Paul Donovan.  "Every time Medinol breaches
 its contract with us and we respond by exercising our legal rights, Medinol
 claims that we wronged them.  That's what they did in the lawsuit they filed
 on April 6, and that's what they've done today.  This latest claim is as
 baseless as the old ones.  The Express stent does not use any of Medinol's
 intellectual property.
     "The NIRFlex design is covered by our Supply Agreement with Medinol and we
 have a license to it," Donovan continued.  "But for more than a year, Medinol
 has refused to send Boston Scientific a single NIRFlex stent, in clear
 violation of the Agreement.  We need to have a more flexible stent design, so
 in response to Medinol's repeated breaches of its obligations, we began the
 development of our own stent, the Express stent.  We are within our rights in
 doing this.  Our program is progressing well, and Medinol is now apparently
 worried about that, so they've decided to attack it.
     "This claim should be viewed in light of Medinol's behavior throughout the
 relationship between the companies," Donovan pointed out.  "Whenever Medinol's
 illegal or erratic actions forced Boston Scientific to act independently,
 Medinol viewed it as a threat and tried to thwart it.  Boston Scientific does
 not intend to let that happen.  The development of our Express stent is
 perfectly appropriate, and we will resist any and all efforts to interfere
 with it."
     Boston Scientific is a worldwide developer, manufacturer and marketer of
 medical devices.  The Company's products are used in a broad range of
 interventional medical specialties.
     This press release contains forward-looking statements.  The Company
 wishes to caution the reader of this press release that actual results may
 differ from those discussed in the forward-looking statements and may be
 adversely affected by, among other things, uncertainties associated with
 litigation, third party supply relationships, and other factors described in
 the Company's filings with the Securities and Exchange Commission.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X37111845
 
 

SOURCE Boston Scientific Corporation
    NATICK, Mass., April 26 /PRNewswire/ -- Boston Scientific Corporation
 (NYSE:   BSX) announced today that Medinol Ltd. has added a claim to its lawsuit
 against the Company alleging that Boston Scientific misappropriated Medinol's
 NIRFlex(TM) stent technology and incorporated it into Boston Scientific's
 internally developed Express(TM) stent.  Medinol is the supplier of the NIR(R)
 stent sold exclusively by Boston Scientific.
     "Apparently, Medinol's game plan is 'the best defense is a good offense',"
 said Boston Scientific spokesman Paul Donovan.  "Every time Medinol breaches
 its contract with us and we respond by exercising our legal rights, Medinol
 claims that we wronged them.  That's what they did in the lawsuit they filed
 on April 6, and that's what they've done today.  This latest claim is as
 baseless as the old ones.  The Express stent does not use any of Medinol's
 intellectual property.
     "The NIRFlex design is covered by our Supply Agreement with Medinol and we
 have a license to it," Donovan continued.  "But for more than a year, Medinol
 has refused to send Boston Scientific a single NIRFlex stent, in clear
 violation of the Agreement.  We need to have a more flexible stent design, so
 in response to Medinol's repeated breaches of its obligations, we began the
 development of our own stent, the Express stent.  We are within our rights in
 doing this.  Our program is progressing well, and Medinol is now apparently
 worried about that, so they've decided to attack it.
     "This claim should be viewed in light of Medinol's behavior throughout the
 relationship between the companies," Donovan pointed out.  "Whenever Medinol's
 illegal or erratic actions forced Boston Scientific to act independently,
 Medinol viewed it as a threat and tried to thwart it.  Boston Scientific does
 not intend to let that happen.  The development of our Express stent is
 perfectly appropriate, and we will resist any and all efforts to interfere
 with it."
     Boston Scientific is a worldwide developer, manufacturer and marketer of
 medical devices.  The Company's products are used in a broad range of
 interventional medical specialties.
     This press release contains forward-looking statements.  The Company
 wishes to caution the reader of this press release that actual results may
 differ from those discussed in the forward-looking statements and may be
 adversely affected by, among other things, uncertainties associated with
 litigation, third party supply relationships, and other factors described in
 the Company's filings with the Securities and Exchange Commission.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X37111845
 
 SOURCE  Boston Scientific Corporation